ASX-listed biotech PharmAust has successfully identified a revamped formulation of its promising anti-cancer drug “Monepantel”. Perth-based PharmAust says that the reformulated Monepantel will improve the drug’s taste and enable the delivery of over 10 times the amount of substance per dose than previously, paving the way for clinical trials ahead of full scale commercialisation.
31/01/2018 - 06:23
PharmAust reformulates Cancer drug to taste better
By Matt Birney
31/01/2018 - 06:23
Related Data & Insights
-
-
Rank Company # 163rd I Synergy Group $1.14m 164th Zelira Therapeutics $1.02m 165th Singular Health $935.18k 166th PharmAust $841.71k 198 public companies - industrial WA ranked by total revenue
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024